JP2006518197A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518197A5
JP2006518197A5 JP2006501525A JP2006501525A JP2006518197A5 JP 2006518197 A5 JP2006518197 A5 JP 2006518197A5 JP 2006501525 A JP2006501525 A JP 2006501525A JP 2006501525 A JP2006501525 A JP 2006501525A JP 2006518197 A5 JP2006518197 A5 JP 2006518197A5
Authority
JP
Japan
Prior art keywords
compound
compound according
lna
ras
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006501525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518197A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2004/000097 external-priority patent/WO2004069992A2/en
Publication of JP2006518197A publication Critical patent/JP2006518197A/ja
Publication of JP2006518197A5 publication Critical patent/JP2006518197A5/ja
Withdrawn legal-status Critical Current

Links

JP2006501525A 2003-02-10 2004-02-10 ラス発現の改変のためのオリゴマー化合物 Withdrawn JP2006518197A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300184 2003-02-10
DKPA200301539 2003-10-20
PCT/DK2004/000097 WO2004069992A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of ras expression

Publications (2)

Publication Number Publication Date
JP2006518197A JP2006518197A (ja) 2006-08-10
JP2006518197A5 true JP2006518197A5 (https=) 2007-03-22

Family

ID=32852146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501525A Withdrawn JP2006518197A (ja) 2003-02-10 2004-02-10 ラス発現の改変のためのオリゴマー化合物

Country Status (6)

Country Link
US (2) US20040248840A1 (https=)
EP (1) EP1592795A2 (https=)
JP (1) JP2006518197A (https=)
AU (1) AU2004209599A1 (https=)
CA (1) CA2515644A1 (https=)
WO (1) WO2004069992A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225495B2 (en) 2002-04-05 2009-01-15 Roche Innovation Center Copenhagen A/S Oligomeric compounds for the modulation HIF-1alpha expression
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20040241717A1 (en) * 2003-02-10 2004-12-02 Santaris Pharma A/S Oligomeric compounds for the modulation of thioredoxin expression
WO2006050732A2 (en) * 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
MX2007005558A (es) 2004-11-09 2008-01-31 Santaris Pharma As Oligonucleotidos de lna potentes para la inhibicion dela expresion de hif-1a.
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US20060234277A1 (en) * 2005-03-31 2006-10-19 Amgen Inc. Method for selectively blocking hemoglobin RNA amplification
US20090069263A1 (en) * 2005-12-16 2009-03-12 Damha Masad J 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
EP2007888A2 (en) * 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
AU2007323469B2 (en) * 2006-11-23 2014-07-24 Guangdong Maijinjia Biotechnology Co., Ltd Oligonucleotides for modulating target RNA activity
EP2001188A1 (en) * 2007-06-08 2008-12-10 F.Hoffmann-La Roche Ag Method for authenticating a medical device and a remote device
DK2171568T3 (en) * 2007-06-29 2018-08-27 Hoffmann La Roche USER INTERFACE FEATURES FOR AN ELECTRONIC DEVICE
WO2009005950A2 (en) * 2007-06-29 2009-01-08 Roche Diagnostics Gmbh Device and methods for optimizing communications between a medical device and a remote electronic device
EP2195428B1 (en) 2007-09-19 2013-12-11 Applied Biosystems, LLC SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF
WO2009068033A2 (en) * 2007-11-26 2009-06-04 Santaris Pharma A/S Lna antagonists targeting the androgen receptor
KR20100105648A (ko) * 2007-12-03 2010-09-29 엔즌 파마슈티칼스, 인코포레이티드 Ｐｉｋ３ｃａ 발현 조절용 ｒｎａ 길항제 화합물
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
KR101913232B1 (ko) * 2010-10-27 2018-10-30 큐알엔에이, 인크. 인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료
AU2012308320C1 (en) 2011-09-14 2018-08-23 Translate Bio Ma, Inc. Multimeric oligonucleotide compounds
US20150315595A1 (en) * 2012-03-12 2015-11-05 Santaris Pharma A/S Compositions and Methods for Modulation of ATXN3 Expression
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
EA201492122A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
US20150247141A1 (en) 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6429264B2 (ja) * 2013-11-12 2018-11-28 学校法人東京理科大学 ボラノホスフェート化合物、及び核酸オリゴマー
US10266828B2 (en) 2013-12-16 2019-04-23 Syddansk Universitet RAS exon 2 skipping for cancer treatment
CN115181778A (zh) 2015-02-04 2022-10-14 百时美施贵宝公司 选择治疗性分子的方法
WO2016127002A1 (en) * 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
US11077132B2 (en) 2015-02-04 2021-08-03 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
US10758558B2 (en) 2015-02-13 2020-09-01 Translate Bio Ma, Inc. Hybrid oligonucleotides and uses thereof
WO2019046698A1 (en) * 2017-09-01 2019-03-07 Thomas Jefferson University COMPOSITIONS AND METHODS FOR MYC GENE MESSENGER RNA INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5935779A (en) * 1988-11-03 1999-08-10 Igen International Inc. Methods for improved particle electrochemiluminescence assay
US5962218A (en) * 1988-11-03 1999-10-05 Igen International Inc. Methods and apparatus for improved luminescence assays
ATE186072T1 (de) * 1991-06-14 1999-11-15 Isis Pharmaceuticals Inc Antisense-oligonukleotid-inhibition des ras-gen
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
IL149694A0 (en) * 1999-12-23 2002-11-10 Exiqon As Therapeutic uses of lna-modified oligonucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20040241717A1 (en) * 2003-02-10 2004-12-02 Santaris Pharma A/S Oligomeric compounds for the modulation of thioredoxin expression
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression

Similar Documents

Publication Publication Date Title
JP2006518197A5 (https=)
US11505569B2 (en) GalNAc phosphoramidites, nucleic acid conjugates thereof and their use
KR101878587B1 (ko) 올리고머 및 올리고머 접합체
US10041074B2 (en) Euchromatic region targeting methods for modulating gene expression
CA3004799C (en) Oligonucleotides for inducing paternal ube3a expression
JP7798836B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP4777777B2 (ja) ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
EP3442983A1 (en) TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
CN104755621A (zh) 癌症治疗
JP2010505432A5 (https=)
JP2010524486A (ja) β−カテニンを調節するためのＲＮＡアンタゴニスト化合物
EP3256591A1 (en) Hybrid oligonucleotides and uses thereof
CN119662650A (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
CN105247052A (zh) B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
KR20190047025A (ko) 변형된 올리고뉴클레오티드 및 사용 방법
WO2016130929A1 (en) Targeting oligonucleotides and uses thereof to modulate gene expression
JP2007533742A5 (ja) 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物
JP2021524277A (ja) Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
JP2012529279A (ja) 新規の強力な抗ａｐｏｂアンチセンス化合物
US20100249219A1 (en) Short rna antagonist compounds for the modulation of hif-1alpha
JP2004526737A5 (https=)
JP2011505798A (ja) Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物
EP4130266A1 (en) Antisense nucleic acid targeting apoc3
WO2018130585A1 (en) Antisense oligonucleotides for modulating relb expression
EP4493694A1 (en) Modified gapmer oligomers and methods of use thereof